Bone Metastasis Market

Market Overview:

The 7 major bone metastasis markets reached a value of US$ 13.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 26.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.25% during 2024-2034.

The bone metastasis market has been comprehensively analyzed in IMARC's new report titled "Bone Metastasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bone metastasis is a kind of advanced tumor that forms when cancer cells spread from their original site of growth into bone tissue. This condition can affect any bone, but it most frequently occurs in the pelvis, spine, and thigh. The common symptoms of the disease include fragile bones, high levels of calcium in the blood, nausea, vomiting, constipation, confusion, loss of urinary or bowel control, weakness in the legs, a low blood cell count, etc. Individuals suffering from bone metastasis may also experience severe pain, anemia, and neurological impairment. The diagnosis of this illness requires a combination of medical history, clinical features, blood tests, and a complete physical examination. Various other diagnostic procedures utilized to confirm a prognosis include X-rays of the affected bone, computerized tomography scans, magnetic resonance imaging, bone scintigraphy, etc. The healthcare provider may also perform a biopsy to determine the features of abnormal cells among patients.

The rising cases of oncological diseases, such as breast cancer and prostate cancer, that cause tumor cells to grow and spread, resulting in an enhanced breakdown of normal bone tissues, are primarily driving the bone metastasis market. In addition to this, the increasing incidences of several associated risk factors, including genetics, previous radiation therapy, noncancerous bone disorders like fibrous dysplasia, etc., are also bolstering the market growth. Furthermore, the widespread adoption of effective bone-building medications, such as bisphosphonates, for reducing bone damage and preventing disease progression is acting as another significant growth-inducing factor. Apart from this, the escalating demand for intravenous radiation using radiopharmaceuticals, owing to its numerous advantages, including high specificity, fewer side effects, and improved patient outcomes, is further creating a positive outlook for the market. Moreover, the increasing utilization of cryoablation, a minimally invasive procedure, to treat this ailment by providing rapid and durable pain relief, is also augmenting the market growth. Additionally, the emerging popularity of targeted therapies, which bind to specific receptors and inactivate the bone remodeling process, thereby inhibiting cancerous cells from expanding and degenerating bones, is further expected to drive the bone metastasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bone metastasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bone metastasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bone metastasis market in any manner.

Recent Developments:

• In March 2024, Sandoz disclosed that the U.S. FDA had approved Wyost (denosumab-bbdz) to prevent skeletal-related events in patients with multiple myeloma and patients with bone metastases from solid tumors.

Key Highlights:

• Bone metastasis occurs in more than 1.5 million cancer patients globally and is most typically associated with malignancies of the prostate, lung, and breast, with an incidence rate of up to 75% of patients with metastatic illness.
• According to the American Cancer Society, around 400,000 new cases of malignant bone metastasis are detected in the United States every year.
• Advanced malignant tumors with bone metastasis have a 30-75 percent incidence, particularly in patients with advanced prostate and breast cancer.
• Prostate cancer had the highest probability of bone metastases (18% to 29%), followed by lung, kidney, and breast cancers.
• In the United States, over 350,000 individuals die each year from bone metastasis.

Drugs:

XGEVA inhibits the development, activity, and survival of bone-breaking osteoclasts by targeting the RANKL pathway. XGEVA is indicated to prevent skeletal-related events in individuals with multiple myeloma and bone metastases from solid malignancies.

MW-032 is under clinical development by Mabwell Shanghai Bioscience for the treatment of bone metastases. It is a recombinant human monoclonal antibody injected subcutaneously. The treatment candidate targets the receptor activator of nuclear factor kappa B ligand (RANKL).

Denosumab biosimilar (LY-01011) is being developed by Luye Pharma Group for the treatment of bone metastases. It is prepared as an injectable and delivered subcutaneously. The therapeutic candidate works by targeting the RANKL.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bone metastasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bone metastasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bone metastasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bone metastasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bone metastasis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bone metastasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of bone metastasis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of bone metastasis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of bone metastasis by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with bone metastasis across the seven major markets?
• What is the size of the bone metastasis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bone metastasis?
• What will be the growth rate of patients across the seven major markets?
   

Bone Metastasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bone metastasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bone metastasis market?
• What are the key regulatory events related to the bone metastasis market?
• What is the structure of clinical trial landscape by status related to the bone metastasis market?
• What is the structure of clinical trial landscape by phase related to the bone metastasis market?
• What is the structure of clinical trial landscape by route of administration related to the bone metastasis market?